Amlodipine is a calcium channel blocker that supports movement of calcium into heart and blood vessels to lower blood pressure and increase the oxygen supply to the heart. Previous studies suggested that the drug should be avoided for patients with heart failure in some instances, but the new findings reveal otherwise.
Researchers from the National Institutes of Health and Glasgow University analyzed the effects of various chemical properties of amlodipine and determined that “[R]emoval of dihydropyridines from the arsenal of drugs available for treating hypertension is not advisable,” they wrote of their findings. Additionally, they noted that the cessation of the drug as a first line of treatment “would have a negative impact on blood pressure control, increasing the risk of secondary morbidities, including myocardial infarction, HF, stroke, retinopathy and kidney disease.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
